Palantir stock drops as UK Parliament slams NHS deal over national security risks

Traders Union
All News
Financial News
Palantir drops 3.96% to $146.34 today

Highlights

UK lawmakers flagged Palantir’s £330 million NHS contract as a national security threat, urging early termination and raising significant UK revenue risk.
Despite regulatory headwinds, Palantir’s Q1 2026 revenue grew 85% year-over-year, bolstered by robust US commercial and government contracts.
Technicals signal short-term bullish momentum but long-term resistance, with price likely to consolidate between $141.00 and $149.00 this week.

Revenue risks intensify as UK regulators challenge NHS deal

On June 3, 2026, UK Members of Parliament designated Palantir’s £330 million NHS agreement as a national security risk and called for early termination by 2027, introducing material revenue risk and heightened regulatory scrutiny for the company’s UK public sector business. In parallel, Palantir reported substantial growth metrics, including 85% year-over-year revenue gains in Q1 2026 and a Rule of 40 score of 145, reflecting robust commercial momentum in the US market. Additional developments include an extended partnership with Thomas Cavanagh Construction Limited through 2035 and news of a new US government contract with the IRS for data system modernization. These positive operational updates have accompanied the regulatory concerns, which remain the dominant headline for the day.

Overbought signals persist as technical momentum wanes

On the technical front, PLTR trades above the SMA-20 ($138.88) and SMA-50 ($141.89) but remains below the SMA-200 ($161.51), with the Ichimoku Kijun at $146.22 acting as immediate support. The MACD indicator is positive with a buy reading, although the ADX is weak at 11.95, indicating a lack of clear trend momentum. Stoch RSI and CCI reflect pronounced overbought conditions, while the Bull/Bear Power (BBP) and intraday movement suggest buyer dominance yet high volatility with a downside bias. Oscillators like RSI and the Awesome Oscillator point to lingering bullish momentum, but divergences and overbought signals underscore short-term vulnerability.

Sideways trading likely as upside remains constrained by resistance

In the near term, typical volatility suggests PLTR will fluctuate within a $141.00 to $149.00 band. The probability of a price increase is low, at under 20%, making further downside more likely. The most probable scenario is for the stock to consolidate in a sideways channel between these support and resistance levels. A bullish outcome would require a sustained breakout above $149.00, while a breakdown below $141.00 could trigger a deeper decline.

Viktoras Karapetjanc, Analysts at Traders Union, sees Palantir’s strong US commercial growth and government adoption as confirming a robust long-term outlook. He notes that UK regulatory risks weigh on short-term sentiment and add uncertainty to the public sector pipeline. Technically, momentum remains, but local overbought signals and volatility limit immediate upside potential. "If regulatory turbulence stabilizes, I expect Palantir to resume its upward trend, with positive fundamentals eventually prevailing over short-term headlines."

Previously, analysts noted Palantir's continued momentum was driven by public sector contracts and broad adoption of its technology, though there were growing warnings about regulatory and concentration risks in the UK. The latest developments introduce a potential shift in outlook, as the UK's heightened scrutiny and calls for early NHS contract termination underscore new downside risk that traders should monitor if PLTR fails to hold above immediate support at $141.00.

Source of Data: PLTR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.